Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Herbal capsule shows promise for heart patients after stent surgery

NCT ID NCT06618495

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a herbal capsule called Xuesaitong (made from Panax notoginseng) can help patients who recently had a heart attack and a stent placed. Sixty adults took the capsule for 4 weeks. Researchers measured changes in platelet genes, proteins, and metabolites to understand how the treatment works and if it is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

60 people

The number who actually took part.

Started

Dec 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * (1) it accords with the diagnostic criteria of western medicine for acute coronary syndrome. (2) within 4 weeks after coronary intervention. (3) 18 years old ≤ age ≤ 80 years old, male or female. (4) voluntarily participate in this clinical trial, give informed consent and sign an informed consent form Exclusion Criteria: * (1) uncontrollable hypertension after drug treatment (systolic blood pressure \> 180mmHg, or diastolic blood pressure \> 110mmHg). (2) increased risk of bleeding: previous history of hemorrhagic stroke; intracranial aneurysms; trauma or major surgery within 1 month (including bypass surgery); diseases currently suffering from active bleeding, etc. (3) patients with history of digestive tract ulcer and massive gastrointestinal bleeding. (4) severe organic heart disease, such as patients with LVEF \< 35% or NYHA/Killip cardiac function grade IV. (5) those with a history of malignant arrhythmias (arrhythmias affected by hemodynamics, requiring drug or electrical cardioversion, or cardiopulmonary resuscitation), congenital heart disease or malignant tumor were considered unable to participate in the trial. (6) severe hepatic and renal insufficiency: glutamic pyruvic transaminase (ALT) or aspartate oxaloacetic transaminase (AST) ≥ 3 × normal upper limit (ULN) or total bilirubin (TBIL) ≥ 2 × ULN; or creatinine clearance (Ccr \< 30ml/min). (7) Women in pregnancy (defined as positive blood pregnancy test) and lactating women. (8) those with a history of blood donation or significant blood loss in the last 3 months (≥ 400ml). (9) people with a previous history of alcoholism (i.e. men drink more than 28 standard units per week and women drink more than 21 standard units per week (1 standard unit contains 14g alcohol, such as 360mL beer or 25mL spirits or 150mL wine with 40% alcohol content); or screen those who drink regularly in the first 6 months (that is, more than 14 standard units per week). (10) those with a history of drug abuse and drug dependence within one year before screening. (11) those who have participated in other clinical trials and taken trial drugs in the past 3 months. (12) people who are allergic or intolerant to aspirin or P2Y12 receptor inhibitors. (13) those who are allergic to the ingredients of the test drugs. (14) other situations in which the researchers think it is not appropriate to participate in this experiment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China

    Beijing, Beijing Municipality, 100091, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.